HER-2/neu and topoisomerase IIα gene amplification and protein expression in invasive breast carcinomas: Chromogenic in situ hybridization and immunohistochemical analyses

American Journal of Clinical Pathology

Volumn 123, Issue 6, 2005, Pages 889-895

  Bhargava, Rohit ^a   Lal, Priti ^a   Chen, Beiyun ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Amplification; Breast carcinoma; Chromogenic in situ hybridization; CISH; HER 2 neu; Overexpression; Topoisomerase II a

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CARCINOMA; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME 17; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DELETION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TUMOR CELL;

EID: 19644388869     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/PCFK8YTQPYWD534F     Document Type: Article

References (26)

1. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 1989;244:707-712.
2. Guerin M, Barrois M, Terrier MJ, et al. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogens Res. 1988;3:21-31.
3. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990;50:4332-4337.
4. Tiwari RK, Borgen PI, Wong GY, et al. HER-2/neu amplification and Overexpression in primary human breast cancer is associated with early metastasis. Anricancer Res. 1992;12:419-425.
5. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
6. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587-2595.
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med. 2001;344:783-792.
8. Pegram MD, Lopez A, Konecny G, et al. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol. 2000;27:21-25.
9. Tsai-Pflugfelder M, Liu LF, Liu AA, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A. 1988;85:7177-7181.
10. Heck MM, Hittelman WN, Earnshaw WC. In vivo phosphorylation of the 170-kDa form of eukaryotic DNA topoisomerase II: cell cycle analysis. J Biol Chem. 1989;264:15161-15164.
11. Rybenkov VV, Ullsperger C, Vologodskii AV, et al. Simplification of DNA topology below equilibrium values by type II topoisomerases. Science. 1997;277:690-693.
12. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with erbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839-847.
13. Penault-Llorca F, Cayre A, Bouchet MF, et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol. 2003;22:1319-1325.
14. Campiglio M, Somenzi G, Olgiati C, et al. Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer. 2003;105:568-573.
15. Jarvinen TA, Liu ET. HER-2/neu and topoisomerase Ilalpha in breast cancer. Breast Cancer Res Treat. 2003;78:299-311.
16. Jarvinen TA, Tanner M, Barlund M, et al. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer. 1999;26:142-150.
17. Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer. 2003;4:179-186.
18. Kallioniemi OP, Wagner U, Kononen J, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet, 2001;10:657-662.
19. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
20. Skacel M, Skilton B, Pettay JD, et al. Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immunohistochem Mol Morphol. 2002;10:-1-6.
21. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res. 2001;61:5345-5348.
22. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase Ilalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 2002;8:1061-1067.
23. Coquelle A, Pipiras E, Toledo F, et al. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell. 1997;89:215-225.
24. Pipiras E, Coquelle A, Bieth A, et al. Interstitial deletions and intrachromosomal amplification initiated from a double-strand break targeted to a mammalian chromosome. EMBO J. 1998;17:325-333.
25. Mueller RE, Parkes RK, Andrulis I, et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer, 2004;39:288-297.
26. Holden JA. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs. Ann Clin Lab Sci. 1997;27:402-412.